Ertapenem is a parenteral carbapenem antimicrobial with pharmacological properties that allow it to be given once daily. This makes it a consideration for outpatient parenteral antimicrobial therapy (OPAT). In comparison with information from the OPAT Outcomes Registry, ertapenem seems well suited for the types of infections and bacteria that are commonly treated with OPAT, plus it has additional activity against anaerobic bacteria. This added spectrum makes it possible to treat complicated skin/skin-structure, complicated intra-abdominal and pelvic infections with a single antibiotic instead of the multiple agents that have usually been required. Ertapenem is also comparable to other OPAT antimicrobials in terms of adverse effects and clinical outcomes. This antimicrobial can be given with any delivery model, although its stability when mixed is such that daily preparation or self-mixing systems need to be considered. Ertapenem should be added to the growing list of once-daily parenteral antibiotics that can be given to outpatients.
Introduction
Intravenous antimicrobial therapy is an essential form of treatment for serious infections. For many years it was thought to be safe to administer intravenous medication in the hospital setting only, but advances in technology, new antimicrobials and pioneering healthcare professionals have changed this strategy. The results of a number of studies indicate that intravenous therapy can now be safely and effectively administered outside the hospital.
Outpatient parenteral antimicrobial therapy (OPAT) has become an integral part of therapy for many infectious diseases and is readily available in most communities in the USA. It can be provided through a variety of programmes, which may be based in hospital clinics, emergency departments, physician offices or the home. 1, 2 Not only has it been demonstrated to be cost-effective, 3 but it also brings a high level of patient satisfaction. 4, 5 With increasing experience, many patients may be started directly on OPAT without hospitalization. Complications of medical care may also be reduced by treating patients with serious infections as outpatients, both in terms of the frequency of nosocomial infections in the hospital and the likelihood of acquiring a healthcare-related infection with bacteria highly resistant to antibiotics.
There are basically three models for the provision of OPAT: the visiting nurse model, the infusion centre model and the self-administration model. The most appropriate model depends on the infection being treated, the characteristics of the antibiotic and the resources available. 2, 6 The traditional visiting nurse model involves sending a nurse to a patient's home to infuse the antibiotic. It has the advantage of providing medical supervision during administration but may be costly in terms of nursing time. The infusion centre model can be provided in a hospital clinic, an emergency department, a physician's office or as a freestanding facility. It has the advantage of providing readily available medical staff and equipment but requires overhead costs and maintenance for the infusion space. It also requires that the patient travel to the facility. The self-administration model consists of training a patient, and often his/her family, in administering intravenous medication. This can be done through the use of gravitydependent systems or infusion devices, which can automatically administer medication. This model requires staff time for training but the overheads are low and nursing time may be reduced.
With any of these three models there is an advantage to be gained by using an antibiotic that can be administered once a day or less frequently. Not only is there an advantage with regard to convenience, but also with regard to compliance-for providers as well as patients. With the economic incentives for OPAT and the potential of this system for improving patient care, the need for new once-daily antibiotics that are safe and effective will only grow.
Ertapenem and OPAT
Ertapenem is a parenteral carbapenem that was approved in November 2001 in the USA for the treatment of complicated intraabdominal infections, community-acquired pneumonia, acute pelvic infections, complicated urinary tract infections, and complicated skin and soft-tissue infections. It may possibly be useful in a variety of other infections because of its potency and in vitro spectrum of Tel: +1-808-586-7452; Fax: +1-808-586-7486; E-mail: alantice@idlinks.com ii84 activity against both aerobic and anaerobic bacteria, 7 but clinical outcomes do not necessarily correlate with in vitro activity. Clinical studies would be needed to support clinical utility in these circumstances. In addition, ertapenem is especially suited for OPAT in that it can be given once a day and appears to be generally well tolerated. 8 Comparative studies have shown that its safety profile is similar to that of ceftriaxone and piperacillin-tazobactam. 8 It has a half-life of ∼4 h. With 1 g infusions, ertapenem reaches at least MIC values for most susceptible pathogens for >20 h for total drug and 4 h for free drug. These values are clearly adequate for the demonstration of in vivo efficacy with once-daily dosing. 9 A study in 146 patients who received ertapenem at 19 OPAT centres in the USA indicated that ertapenem had a cure rate that was comparable to that of piperacillintazobactam (83% and 82%, respectively) and a low rate of adverse effects in this setting. 10 Intravenous infusions may be associated with phlebitis, for which a peripherally inserted central catheter or other central line may be appropriate if a course of more than 1 week duration is anticipated. Infusion pumps are seldom needed with once-daily administration but may be used to control rates and assure delivery with minimal maintenance by the patient. Ertapenem may lose 5% of its activity over 6 h at room temperature after it is mixed with normal saline. This short stability factor is not a problem if it is given in infusion centres where it is mixed daily. It is, however, a limiting factor for the selfinfusion model, which may mix and dispense medications for use over 3-4 days. It is easy to deal with this by having patients mix their own medication. They can either use standard methods or special systems with a compartment for ertapenem and one for the solution with a barrier that can be easily ruptured. Ertapenem can also be given intramuscularly (with lidocaine) as well as intravenously, with a low incidence of adverse effects or early discontinuation. 9 The OPAT Outcomes Registry has been developed from a network of providers from more than 20 centres in the USA and internationally over the past 5 years. It now has accumulated information on over 12 000 patients who have received more than 14 000 courses of OPAT. These data now serve as a resource with which to evaluate the potential value and safety of new intravenous antibiotics in OPAT, and to compare different antimicrobial agents in this setting. 4, [11] [12] [13] Current information from the OPAT Outcomes Registry is shown in Table 1 . The most frequent infections treated with OPAT are skin and soft-tissue infections (22%), osteomyelitis (15%), followed by septic arthritis (6%) and wound infections (4%) (www. OPAT.com). However, ertapenem has not been studied for the treatment of osteomyelitis or septic arthritis. The most common infections treated are those caused by Gram-positive cocci, especially Staphylococcus aureus (37%) and streptococci (12%). Coagulasenegative staphylococci (9%) also play a significant role when prosthetic devices and foreign materials are in place. Pseudomonas aeruginosa was reported in 8% of cases (www.OPAT.com).
The frequency of adverse effects serious enough to discontinue an antibiotic is also reported in the OPAT Outcomes Registry. 11,13 This is important because such events may occur outside the hospital setting. The incidence of reactions that are serious enough to stop therapy with a specific antimicrobial varies from 3% to 10% for the top 10 most frequently used drugs. Table 1 indicates that the most frequent reason for stopping an antibiotic is rash (2.1%), although antimicrobials differ in the frequency with which it occurs (2.0-8.0%) during the course of therapy. 13 Less common adverse effects include fever (0.6%), nausea (0.5%) and diarrhoea (0.3%).
Although less than 100 reports about ertapenem have accumulated in the OPAT Outcomes Registry for statistical comparison, information from clinical trials can be compared with an aggregate of Registry information. The types of infections most commonly treated with OPAT (Table 1 ) match the indications for ertapenem, and the antimicrobial spectrum of ertapenem covers the most frequently isolated bacteria. 1,2,7,10 The additional anaerobic spectrum of ertapenem raises the possibility of expanding the indicated infections for OPAT to include mixed infections, such as complicated skin/skin-structure, complicated intra-abdominal and pelvic infections with a single once-daily antibiotic. Exceptions to the antimicrobial spectrum of ertapenem include methicillin-resistant staphylococci, which are becoming more frequent. Pseudomonas strains are also outside the spectrum of ertapenem but comprise only a small number of cases, which are often associated with specific diseases such as cystic fibrosis or bronchiectasis. The effectiveness of intravenous antibiotics used in the outpatient setting has been demonstrated with the information collected from the OPAT Outcomes Registry. 4 ,11 A high level of effectiveness (83%) has also been found with ertapenem with OPAT. 10 The frequency of adverse events serious enough to stop therapy with ertapenem has been reported to be 4.7%, which is well within the safety range of other OPAT antibiotics. 13 The types of adverse reaction are also comparable and consistent with those usually expected with β-lactam drugs. Table 2 displays the antimicrobials that come in an intravenous form and might be considered for once-daily OPAT on the basis of their properties. Ceftriaxone has been the pioneer in OPAT because of its half-life of 6-10 h. Other antimicrobials with even longer halflives, such as azithromycin, caspofungin, doxycycline, gatifloxacin, metronidazole and trimethoprim-sulfamethoxazole, could also be considered for once-daily therapy even though insufficient data have been presented to the US Food and Drugs Administration (FDA) to justify that dosing for some of them. Other drugs, such as ertapenem and levofloxacin, have a somewhat shorter half-life but have received 
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FDA approval for once-daily administration owing to their t > MIC profiles and efficacy data from clinical trials. Aminoglycosides, such as gentamicin and tobramycin, have considerably shorter half-lives but are best given once daily because of their mechanism of action and toxicity. They are not yet approved by the FDA for this, however. Their killing capacity is related to their peak concentration and they have a long post-antibiotic effect, which allows levels to fall below the therapeutic range for part of a day. The trough concentration may also correlate with reduced toxicity. 17 Vancomycin is commonly given every 12 h because of its half-life of 6 h in patients with normal renal function-even though the FDA still recommends dosing every 6-12 h. In the elderly, however, the half-life is prolonged, even in those with apparently normal renal function. 18, 19 Teicoplanin is another good once-daily antimicrobial for Gram-positive bacteria, but is not available in the USA. Renal failure may also have a major effect on the excretion of many antimicrobials, which allows infrequent administration. Dosing of vancomycin, cefazolin or the aminoglycosides may be needed only after dialysis, or as seldom as once a week. The antimicrobial spectrum of the antimicrobials that might be used once daily with OPAT is now such that almost any infection can be treated outside the hospital. Exceptions include serious P. aeruginosa and other Gram-negative infections that are resistant to quinolone or carbapenem therapy. The increasing frequency of methicillinresistant staphylococci also presents a challenge that is not covered by ertapenem or the cephalosporins.
The stability of an antimicrobial once it has been mixed is also an important consideration in OPAT. With the self-administration delivery model, solutions are often made up and dispensed to patients 3 or 4 days in advance and then stored at home in a refrigerator until used. If the medication is less stable, such as with ertapenem and trimethoprim-sulfamethoxazole and some of the penicillins, the daily infusion centre model may be more appropriate. For those who still wish to self-administer, it is possible to use closed systems that allow the patient to mix their own medication just before administration. This also avoids the need to warm up a refrigerated pre-mixed solution-and eliminates some pharmacy costs as well.
In the USA, the necessary steps have already been taken to assure reimbursement for ertapenem with OPAT. Specific codes have been assigned to the drug in addition to the OPAT services and physician visits. Private payers are often interested in having patients discharged on OPAT and hence will facilitate payments for charges and codes submitted. Medicare does not reimburse for OPAT at home but does pay, under certain circumstances, for its use in physicians' offices and in hospital clinics. Other practical aspects of OPAT can be found on the OPAT website (www.OPAT.com) and in the Infectious Diseases Society of America guidelines on OPAT. 2 In general there is not a problem with reimbursement for ertapenem given in emergency departments or long-term care facilities.
In addition to OPAT, ertapenem will probably be useful in other outpatient or ambulatory care settings such as emergency departments, where the first dose of an antibiotic may be particularly important in treating a life-threatening or evolving infection with an antimicrobial identical to that which would be given if the patient were hospitalized. Long-term care facilities, with a need for prompt and effective antimicrobial levels in a debilitated population, may also benefit from ertapenem, especially its ability to be given intramuscularly.
Conclusion
In summary, ertapenem is a once-daily intravenous carbapenem antimicrobial that appears to offer a new opportunity for OPAT. Preliminary studies indicate that ertapenem is generally comparable to other intravenous antimicrobials used in OPAT in terms of effectiveness, tolerability and adverse events. It also has the capacity to extend the spectrum of OPAT to mixed anaerobic and aerobic infections. This should allow outpatient therapy of complicated skin/skin-structure, ii86 complicated intra-abdominal and pelvic infections with one antibiotic once a day.
